Inhibitory effect of curcumin on the Al(III)-induced Aβ42 aggregation and neurotoxicity in vitro  by Jiang, Teng et al.
Biochimica et Biophysica Acta 1822 (2012) 1207–1215
Contents lists available at SciVerse ScienceDirect
Biochimica et Biophysica Acta
j ourna l homepage: www.e lsev ie r .com/ locate /bbad isInhibitory effect of curcumin on the Al(III)-induced Aβ42 aggregation and
neurotoxicity in vitro
Teng Jiang a, Xiu-Ling Zhi b, Yue-Hong Zhang a, Luan-Feng Pan b,⁎, Ping Zhou a,⁎⁎
a State Key Laboratory of Molecular Engineering of Polymers, Department of Macromolecular Science, Fudan University, Shanghai, China
b Laboratory of Molecular Biology, Shanghai Medical College, Fudan University, Shanghai, ChinaAbbreviations: AD, Alzheimer's disease; Aβ42, amylo
CD, circular dichroism; ThT, thioﬂavin T; AFM, atomic
ﬂuoroisopropanol; CBB, Coomassie Brilliant Blue; A595
595 nm
⁎ Correspondence to: L.-F. Pan, Laboratory of Molecu
College, Fudan University, Shanghai 200032, China. Tel.
⁎⁎ Correspondence to: P. Zhou, State Key Laboratory of
mers, Department of Macromolecular Science, Fudan Univ
Tel./fax: +86 21 55664038.
E-mail addresses: lfpan@shmu.edu.cn (L.-F. Pan), pi
(P. Zhou).
0925-4439/$ – see front matter © 2012 Elsevier B.V. All
doi:10.1016/j.bbadis.2012.04.015a b s t r a c ta r t i c l e i n f oArticle history:
Received 20 February 2012
Received in revised form 12 April 2012
Accepted 20 April 2012
Available online 25 April 2012
Keywords:
Alzheimer's disease
Protein conformation
Aggregate morphology
Fibrillation inhibitorThe pathogenesis of Alzheimer's disease (AD) involves a key event which changes themorphology of amyloid-β
42 (Aβ42) peptide from its soluble monomeric form into the ﬁbrillated aggregates in the brain. Aluminum ion,
Al(III), is known to act as a pathological chaperone of the Aβ42 in this process; curcumin, a natural phenolic com-
pound, is considered capable of binding Al(III) and Aβ42; nevertheless, little is known about the combined action
of curcumin and Al(III) on the Aβ42 ﬁbrillation and neurotoxicity. Here, combinations of circular dichroism spec-
troscopy, thioﬂavin T ﬂuorescence, atomic force microscopy, Bradford and MTT assays, it is demonstrated that
although Al(III) can promote the Aβ42 ﬁbrillation dose-dependently, leading to the high neurotoxicity to PC12
cells, curcumin can inhibit the events. Besides, we found that curcumin is able not only to inhibit the formation
of Al(III)-induced Aβ42ﬁbrillation, but also to form the Al(III)–curcumin complexeswhich in turn can remold the
preformed, mature, ordered Aβ42 ﬁbrils into the low toxic amorphous aggregates. These ﬁndings suggest that
curcumin could block the binding of Al(III) with Aβ42 and form the Al(III)–curcumin complexes, so as to inhibit
the Al(III)-induced Aβ42 ﬁbrillation and neurotoxicity. The Al(III)–curcumin complexes areworth potentially de-
veloping as a therapy agent against the neurodegenerative disorders in the future.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
Amyloid plaques and neuroﬁbrillary tangles, containing amyloid-
β (Aβ) peptides and tau proteins respectively, are conceived as two
pathological hallmarks of Alzheimer's disease (AD). The progressive
accumulation of Aβ aggregates via a ﬁbrillation process is widely be-
lieved fundamental to initialize the neurodegenerative pathology and
trigger a cascade of events which include neurotoxicity, oxidative
stress and inﬂammation during the progression of AD [1–3]. The Aβ
ﬁbrillation involves the dimer and oligomer formation, and their
growth into the protoﬁbrils and ﬁbrils via a complicated multistep-
nucleated polymerization process [4]. Nowadays, the emerging role
of soluble entities, oligomers, in the neurodegenerative disorders is
widely accepted, putting aside the old idea which considers that theid-β 42; Al(III), Aluminum ion;
force microscopy; HFIP, hexa-
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rights reserved.ﬁbrils and neuritic plaques are the primary entities responsible for
the disease [5,6]. Accordingly, new attempts have been carried out
to search for the therapeutic agents which can inhibit the formation
of toxic oligomers and remold the preformed ﬁbrils into non-toxic
components instead of toxic ﬁbril precursors [7]. Nonetheless, only
limited experimental results of those agents have been reported and
the action mechanism of the agents is still ambiguous.
Some metal ions have been demonstrated as the potential risk co-
factors in the neurodegenerative disorders [8,9]. These metal ions,
such as Fe3+, Al3+, accelerate the dynamic process of Aβ aggregation,
thus enhancing the neurotoxicity on the neuronal cells, as a conse-
quence of marked alterations of biophysical properties of the peptide
[9–11]. It is worth noticing that among those metal ions, Al(III),
absorbed or accumulated in human body via diet, antacids, cosmetics,
fumes and particles from the occupational exposure [12], is a compo-
nent in the senile plaques and suggested promoting Aβ aggregation
and increasing Aβ neurotoxicity efﬁciently [13–15]. It is evidenced
that Al(III) accumulated in AD brain accelerates the generation of
Aβ peptide due to the faulty proteolysis of normal amyloid precursor
protein [16,17], meanwhile, Al(III) inhibits the proteolytic degrada-
tion of Aβ peptide via cathepsin D, triggering the intracellular accu-
mulation of Aβ peptide [14]. Therefore, many primary therapeutic
goals are targeted at reducing the metal-induced Aβ aggregation
into toxic components. One of the therapeutic strategies is develop-
ment of the agents that can chelate metal ions [18,19] to prevent
Fig. 1. Molecular structure of curcumin.
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tenuate the metal-induced redox activity and neurotoxicity of the
peptides.
Recently, a series of potential small molecule drugs, concerned with
neurodegenerative disorders, were reported [20]. Among them, cur-
cumin (Fig. 1), a natural product having potent antioxidant and anti-
inﬂammatory activities, is under development as a potential chemo-
therapeutic agent of cancer and neurodegenerative disorders [21,22].
Previous studies have also shown that curcumin can interact with Aβ,
thus inhibiting the Aβ aggregation and deposition [23], even disrupting
the existing plaques, and partially restoring the distorted neuritis
[24,25]. In addition, curcumin can readily chelate the metal ions, such
as Cu2+, Zn2+, Al3+, Fe3+ and Mn2+ [26–31], to form the complexes,
reducing the metal-induced Aβ neurotoxicity. Though curcumin has
been demonstrated safe and efﬁcient as a chemotherapeutic agent, its
pharmaceutical role is still restricted because of its low aqueous solubil-
ity, inadequate tissue absorption and degradation at alkaline pH, which
severely curtail its bioavailability [32,33]. Because of those disadvan-
tages of the curcumin, modiﬁcation of the curcumin structure and de-
velopment of the potential delivery systems have been suggested to
improve the aqueous solubility, stability and bioavailability of the cur-
cumin [34–36]. In addition, it is reported that metal–curcumin com-
plexes have the protective roles against stress, free radical and
neuronal damage [26,28,31]. Hence, new strategy concerning the roles
of metal–curcumin complexes in AD treatment is very attractive.
Since curcumin canbindAl(III) to form three types of Al(III)–curcumin
complexes in molar ratio of 1:2, 1:1, 2:1, as characterized by 27Al nuclear
magnetic resonance and mass spectroscopy as well as density functional
theory calculation in our previous work [30], we speculate that curcumin
mayhave ability to block the interactionbetweenAl(III) andAβ42, and the
formed Al(III)–curcumin complexes which are highly soluble [30] could
be more effective in reducing the Aβ42 ﬁbrillation and neurotoxicity
than curcumin alone.
In the present study, we used circular dichroism (CD) spectrosco-
py, thioﬂavin T (ThT) ﬂuorescence, atomic force microscopy (AFM),
Bradford and MTT assays to investigate the relationship among cur-
cumin, Al(III) and Aβ42 morphologies and its neurotoxicity. The rela-
tionship was rationalized on the molecular and cellular basis in the
present work, and the Al(III)–curcumin complexes were demonstrat-
ed capable of reducing the ﬁbrillation and neurotoxicity of Aβ42.190 200 210 220 230 240 250
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Fig. 2. Inhibitory effect of curcumin on Al(III)-induced conformational alteration of
Aβ42. CD spectra of Aβ42 (40 μM) samples incubated for 3 days in the absence (solid
line in black) and in the presences of Al(III) (short dash dot in red), curcumin (dash
dot in blue) and both curcumin (10 μM) and Al(III) (10 μM) (short dash in dark
cyan), respectively.2. Materials and methods
2.1. Preparation of Aβ42 aggregates
Aβ42 was purchased from GL Biochem Ltd. (Shanghai, China). Firstly,
Aβ42 peptide was dissolved in hexaﬂuoroisopropanol (HFIP) to a concen-
tration of 1 mg/mL, and sonicated in water bath for 5 min and stood for
1 h at room temperature; then the Aβ42 solution was separated into ali-
quots in microcentrifuge tubes, freeze-dried under high vacuum and
stored at−20 °C. Immediately prior to the use, the HFIP-treated Aβ42 al-
iquots were dissolved in 0.2 M NH3⋅H2O [13,37] to the concentration of
2.0 mg/mL for 1 h at room temperature, and then diluted to 0.5 mg/mL
with TBS (5 mM Tris, 20 mM NaCl), and adjusted to pH 7.4 by HCl. The
ﬁnal concentration of NH4+-contained ions in the Aβ42 solution was
50 mM. Thepeptide solutionswere thenﬁltered through a0.22-μmsyrin-
ge ﬁlter removing any large species. For study of Al(III) and curcumininteraction with Aβ42, the previously prepared Aβ42 solution were
mixed with various volumes of 0.5 mM AlCl3 aqueous solution
(pH=4.5) and thendiluted by sterilized distilledH2O to theﬁnal solution
of 40 μMAβ42 with 5.0, 7.5, 10.0 and 15.0 μMAl(III); or the ﬁnal solution
of 40 μM Aβ42 with 10.0 and 15.0 μM curcumin; or the ﬁnal solution of
40 μM Aβ42 with 10 μM curcumin and 5.0, 7.5, 10.0, 15.0 and 20.0 μM
Al(III). The samples were incubated at 37 °C from 0 to 6 days in 0.5 mL
Eppendorf tubes, and someof sampleswere taken out at the desired incu-
bation time and frozen in −20 °C. After thawed, samples of 200 μL,
200 μL, 5 μL, 100 μL and 50 μL were used for the measurements of CD,
ThT ﬂuorescence, AFM, Bradford and MTT assay, respectively.2.2. Remolding of preformed Aβ42 aggregates with curcumin
40 μM Aβ42 solution with 10 μM Al(III) incubated at 37 °C for
3 days were mixed with 10 μM curcumin at 37 °C for additional
3 days of incubation. The samples were taken out at the desired incu-
bation time and frozen at −20 °C. After thawed, the samples of
200 μL, 200 μL, 5 μL and 50 μL were used for the measurements of
CD, ThT ﬂuorescence, AFM, Bradford and MTT assay, respectively.2.3. CD spectroscopy
CD spectrum of Aβ42 was recorded by a Jasco spectropolarimeter
with a quartz cell of 1 mm path length. 200 μL of the incubated sam-
ples was used for CD measurement. CD spectra were measured at
wavelength from 190 to 250 nm with a scan speed of 100 nm/min
and accumulation of ﬁve scans. A blank control (20 mM phosphate
buffer, pH 7.4) was subtracted from the studied spectra.2.4. ThT ﬂuorescence assay
The ﬁbrillation of Aβ42was evaluated by ThT ﬂuorescencewith a ﬂuo-
rescence spectrophotometer (FLS-920, Edinburgh Instruments). 200 μL of
Aβ42 solution incubated as described abovewas added into 800 μL ThT so-
lution (15 μMThT in 5 mMTBS, pH 7.4). The ﬂuorescence of Aβ42 sample
in a quartz cuvette with the light-path of 1 cmwas excited at wavelength
of 450 nmand recorded at emissionwavelength of 485 nm. The spectrum
was scanned twice and subtracted by free ThT ﬂuorescence. All ﬂuores-
cence experiments were repeated three times and averaged along with
standard deviation. The ThT ﬂuorescence curves were ﬁtted with a sig-
moidal model using Sigmoidal Fit packaged in Origin 7.5 software.
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5 μL of above incubated samplewas freshly collected and swiftly dilut-
ed to 5 μg/mL solutionwith TBS (5 mMTris, 20 mMNaCl). 10 μL of the di-
luted samplewasmounted onto the freshly cleavedmica for 5 min, gently
rinsedwith deionizedwater, anddried in vacuumovernight. Imageswere
acquired under atmosphere using the silicon probe in a tapping mode
packaged in multi-mode SPM Nanoscope IV system (Veeco Metrology
Group, USA).
2.6. Bradford protein assay
Coomassie Brilliant Blue (CBB) staining is one of the popular methods
for the protein analysis. The concentrations of the pre-incubated Aβ42
samples were measured using Bradford assay. Brieﬂy, 100 μL of each
pre-incubated Aβ42 sample was centrifuged at 16,000 g for 8 min at
4 °C. 80 μL of the supernatantwas dilutedusing 360 μL CBB-G250 solution
and then incubated for 5 min at room temperature. The absorption at
595 nm (A595) was measured by a Bio-Rad plate reader. The values
were averaged from four parallel wells for each Aβ42 sample and control
(without Aβ42). All experiments were run with three replicates.
2.7. Cell cultures and MTT assay
Cell cultures and MTT assay were performed as described elsewhere
[38]. Brieﬂy, PC12 cells were grown in Dulbecco's modiﬁed Eagle's medi-
um(DMEM) containing 10%horse serum, 5% fetal bovine serum(FBS), 1%
L-glutamine (3.6 mM), and 1% penicillin/streptomycin antibiotics in 5%
CO2 at 37 °C. Cells were harvested from ﬂasks and plated in 96-well poly-
styrene plates (Corning Inc., Corning, NY) with approximately 10,000
cells in 100 μL of medium per well. Cells were incubated at 37 °C for
24 h to attach the plates. 50 μL of each pre-incubated Aβ42 sample at
given incubation time was diluted with fresh medium and added35000
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Fig. 3. Fibrillation kinetics of Aβ42 (40 μM) on Al(III), curcumin and their mixture treatment
Aβ42 ﬁbrillation kinetics on Al(III) concentrations (a: 0 μM, ■ in black; b: 5 μM, in blue; c:
results on sigmoidal function. B) Aβ42 ﬁbrillation kinetics on curcumin concentrations (a: 0 μ
on the absence (a:■ in black) or presence of 10 μM curcumin and various concentration of A
olive; e: 10 μM,▼ in orange; f: 15 μM,● in red; and g: 20 μM, ♦ in green. D) Comparison of A
10 μM curcumin (c: ▲ in olive) and their mixture (d: in red).individually to the cellwell. Theﬁnal concentration of Aβ42 in each culture
well with or without Al(III) and curcumin was 1 μM. The same volume of
medium was added into control cultures (only PC12 cells present). The
cells were then incubated for additional 60 h at 37 °C. At the end of incu-
bation, the cell viability was determined by MTT assay. Firstly, the pre-
incubated medium in each well was aspirated carefully, and then 100 μL
fresh DMEM with 0.75 mg/mL thiazolyl blue tetrazolium bromide was
added into each well. After incubation for additional 4 h at 37 °C, the
formed crystals were dissolved by addition of 150 μL DMSO each well
with shaking for 15 min at room temperature. The absorbance at
490 nmwasmeasured by a Bio-Radmulti-well assay plate reader and av-
eraged by ﬁve replicated wells for each sample as well as control. Cell vi-
ability was calculated by the ratio of the absorbance of cells with Aβ42
presence to that without Aβ42 presence. Data were collected from three
independent experiments. The standard deviations were analyzed by
one-way ANOVA packaged in Origin 7.5 software.
3. Results
3.1. Impact of Al(III) and curcumin on the secondary structure and
ﬁbrillation of Aβ42
To investigate curcumin effect on the Al(III)-induced conforma-
tional transition of Aβ42, CD spectroscopy was applied to observe
the changes in secondary structures of the Aβ42 at different concen-
trations of Al(III) and curcumin, after the samples were incubated
for 3 days. As shown in Fig. 2, the conformation conversion of Aβ42
is inhibited by curcumin from a physiological unfolded random coil
to a folded β-sheet, which is demonstrated by less negative band at
217 nm, when compared with that of Aβ42 alone; while in the pres-
ence of Al(III), CD spectrum shows an increase in the negative band
at 217 nm, which indicates a structural change into β-sheet. Intrigu-
ingly, when addition of curcumin into the Al(III)/Aβ42 mixed samples,35000
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s were monitored by ThT ﬂuorescence at 485 nm for 6 days; error bars = SD, n=3. A)
7.5 μM, ○ in red; d: 10 μM, □ in green; and e: 15 μM, ● in olive). Solid lines are ﬁtting
M,■ in black; b: 10 μM,○ in blue; and c: 15 μM,▼ in olive). C) Aβ42 ﬁbrillation kinetics
l(III) ranging from 0 to 20 μM (b: 0 μM,□ in blue; c: 5 μM,○ in magenta; d: 7.5 μM,▲ in
β42 ﬁbrillation in the absence (a:■ in black) or presence of 10 μM Al(III) (b: ○ in blue),
Fig. 4. AFM images of the morphologies of Aβ42 aggregates incubated (A) in the absence, in the presence of (B) 10 μM Al(III), (C) 10 μM curcumin and (D) their mixture at different
incubation time, respectively.
1210 T. Jiang et al. / Biochimica et Biophysica Acta 1822 (2012) 1207–1215the spectrum appears a broad negative band around 206 nm which is
attributed to the mixture of random coil, beta-sheet and alpha-helix
structures. The results suggest that the formed Al(III)–curcumin com-
plexes could prevent Aβ42 from converting into a folded conforma-
tion more effectively than curcumin.
ThT ﬂuorescence has been widely used to detect the β-sheet con-
formers and their aggregates of Aβ42 [39,40]. Therefore, in the present
work, to examine the inhibitory effect of curcumin on Al(III)-induced
Aβ42 ﬁbrillation, ThT ﬂuorescence was used to detect the amyloid ﬁbrils
of Aβ42 incubated with Al(III) in the absence or presence of curcumin.
ThT ﬂuorescence intensity of Aβ42 alone shows initially a low plateau
phase, called as lag phase during the ﬁrst 2 days of incubation, and then
increases from 2 to 5 days, and ﬁnally reaches to a high plateau after
5 days of incubation (Fig. 3A-a). In the presence of Al(III), the lag phases
are shortened gradually as the concentration of Al(III) increased
(Fig. 3A-b, c, d, e), meanwhile, the slope of the exponential phase and
the ﬂuorescence intensity of the ﬁnal plateau considerably increase in a
dose-dependent manner. In contrast, the amyloid formation of Aβ42 is
somewhat suppressed by curcumin, as demonstrated by the decrease inboth the corresponding ﬂuorescence intensity and the slope of the expo-
nential phase (Fig. 3B). Furthermore,when incubation of Aβ42 in the pres-
ence of 10 μM curcumin with various concentration of Al(III) ranging
from 0 to 20 μM, the signiﬁcantly lower ﬂuorescence intensity of Aβ42 is
shown in Fig. 3C, compared with those without curcumin. During 2 to
6 days of incubation, it is surprising to ﬁnd that the Aβ42 sample incubat-
ed with Al(III)/curcumin mixture at molar ratio of 1:1 has a reduction in
the ﬂuorescence intensity in Fig. 3D, compared with that in the presence
of curcumin only. These ﬁndings indicate that curcumin has ability to pre-
vent Aβ42 from the Al(III)-induced ﬁbrillation, and the Al(III)–curcumin
complexes formed in molar ratio of 1:1 might have stronger ability to in-
hibit the ﬁbrillation of Aβ42 (Fig. 3D).
3.2. Morphologies of aggregates detected by AFM
AFM experiments were carried out to observe the morphologies of
Aβ42 incubated in the presence or absence of Al(III) and curcumin
from 1 to 5 days (Fig. 4). In Fig. 4A, the control sample (Aβ42 alone)
shows a characteristic ﬁbrillation process which is in agreement
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1211T. Jiang et al. / Biochimica et Biophysica Acta 1822 (2012) 1207–1215with above results. After incubation for 1 day (Fig. 4A-day 1), the
small oligomers are observed in the control sample. Those oligomers
prolong into the protoﬁbrils or ﬁbrils after 3 or 5 days of incubation
(Fig. 4A-day 3 and day 5). When co-incubation of Aβ42 with Al(III),
the amount of oligomers after incubation for 1 day (Fig. 4B-day 1)
and the ﬁbrils after incubation for 3 days or 5 days (Fig. 4B-day 3
and day 5) increase, which is consistent with CD results (Fig. 2) and
ThT ﬂuorescence results (Fig. 3). Intriguingly, in the presence of
10 μM curcumin, the oligomeric aggregates decrease after incubation
for 1 day (Fig. 4C-day 1). Further 2 days or 4 days of incubation, the
Aβ42 assemble into the amorphous aggregates dramatically instead
of the protoﬁbrils or ﬁbrils (Fig. 4C-day 3 and day 5). To substantiate
the inhibitory effect of curcumin on the Al(III)-induced Aβ42 ﬁbril for-
mation, 10 μM curcumin was added into the Aβ42 samples in the
presence of 10 μM Al(III), as seen from Fig. 4D, the amount of oligo-
mers is substantially less than that in the control sample (Fig. 4D-
day 1). Besides, during further incubation, only a few amorphous ag-
gregates instead of ﬁbrils are observed (Fig. 4D-day 3 and day 5). Ev-
idently, the morphologies of Aβ42 aggregates are very different
between presence and absence of curcumin and Al(III) during the in-
cubation. These ﬁndings clearly demonstrate that curcumin shows a
strongly inhibitory effect on the Al(III)-induced ﬁbrillation of Aβ42,
and the formed Al(III)–curcumin complexes promote the formation
of amorphous aggregates of Aβ42, but prevent their further develop-
ment into the ﬁbrillar amyloids.[ A
4
[ A
4
1 2 3 4 5
50
60
70
80
90
100
d
c
b
a
Ce
ll 
vi
ab
ili
ty
 %
 c
on
tro
l
Incubation time (day)
B
Fig. 6. A) Comparison of neurotoxicity of Aβ42 after pre-incubation for 1 day at 37 °C in-
cubated in the absence and in the presences of Al(III), curcumin and Al(III)–curcumin
complex, respectively; error bars = SD, n=4. B) Dependence of Aβ42 neurotoxicity to-
ward PC12 cells on the incubation time in the absence (■ in black) and in the presences
of 10 μM Al(III) (○ in blue), 10 μM curcumin (▲ in olive) and their mixture ( in red),
respectively; error bars = SD, n=4; *: pb0.05; **: pb0.01.3.3. Peptide analysis by the Bradford assay
To determine the concentration of the un-aggregated peptide in each
incubated sample, Bradford assay was used to measure the peptide con-
centration in the supernatants of the pre-incubated Aβ42 samples. The
peptide is quantiﬁed based on the absorbance of peptide-Coomassie Bril-
liant Blue (CBB) complexes at wavelength of 595 nm. In Fig. 5, curve-a
shows the absorbance of Aβ42–CBB complexwithout Al(III) and curcumin
presence. The absorbance decreases gradually as the incubation time in-
creased,which implies that the Aβ42monomersmay assemble into the ﬁ-
brils continuously during incubation, agreeablewith AFM result in Fig. 4A.
The curve-b, curve-c and curve-d in Fig. 5 showAl(III), curcumin and their
complexes how to affect the absorbance of the Aβ42–CBB complexes at
595 nm, respectively. A595 values in the presence of Al(III) (curve-b in
Fig. 5) are lower than that of Aβ42 alone, indicating that Al(III) accelerates
the formation of Aβ42ﬁbrils orﬁbril plaques, agreeablewith AFM result in
Fig. 4B. When incubation of Aβ42 with curcumin presence for 2 or 3 days,
the absorbance of the Aβ42–CBB complexes is the lowest (curve-c in
Fig. 5), revealing that there exist the least un-aggregated peptides in the
samples during the incubation period; while in the presence of bothcurcumin and Al(III), the absorbance of the Aβ42–CBB complexes is al-
ways the highest (curve-d in Fig. 5), which means that more un-
aggregated peptides exist in the incubated samples.3.4. Neurotoxicity of Aβ42 in the presence or absence of curcumin and
Al(III)
We determined the neurotoxicity of the Aβ42 toward PC12 cells with
or without curcumin and Al(III) presence by MTT assay. Fig. 6A demon-
strates that when incubation of PC12 cells with 250 nM curcumin or
Al(III), respectively, few reduction in the viability of PC12 cells is observed
as compared with that of normal control group (DMEM without Aβ42,
Al(III) and curcumin presence). Similar results are observed when co-
incubation of PC12 cells with curcumin and Al(III) (Fig. 6A). In contrast,
when further co-incubation of PC12 cells with the Aβ42 samples pre-
incubated for 1 day at 37 °C already, the PC12 cell viability is reduced by
37%, which indicates that the pre-incubated Aβ42 exhibits the substantial
neurotoxicity (Fig. 6A). On the other hand, when further co-incubation of
PC12 cells with the Aβ42 sample pre-incubated with different concentra-
tion of Al(III), the Aβ42 aggregates with low or high concentration of
Al(III) presence attenuate signiﬁcantly the cell viability to 53±0.8% or
46±1.4%, respectively, comparedwith the cell viability of 63±2.4%with-
out Al(III) presence. The results indicate that Al(III) promotes substantial-
ly the neurotoxicity of Aβ42 dose-dependently (Fig. 6A). However, when
1212 T. Jiang et al. / Biochimica et Biophysica Acta 1822 (2012) 1207–1215further co-incubation of PC12 cells with the Aβ42 sample pre-incubated
with curcumin for 1 day, Aβ42 shows a decrease in neurotoxicity
(Fig. 6A). Intriguingly, when further co-incubation of PC12 cells with the
Aβ42 (40 μM) sample pre-incubated with curcumin (10 μM) and Al(III)
(10 μM) for 1 day, curcumin shows a protection against the Aβ42 neuro-
toxicity promoted by Al(III), as shown in Fig. 6A. It is worth noticing
that the formed Al(III)–curcumin complexes attenuate the Aβ42 toxicity
more substantially than curcumin alone (Fig. 6A), and the Al(III)–
curcumin complex formed at [Al(III)]/[curcumin] molar ratio of 1:1
attenuate the Aβ42 toxicity in a dose-dependent manner as well.
Fig. 6B shows the dependence of PC12 cells viability on the Aβ42
pre-incubated from 1 to 5 days at 37 °C in the presence or absence
of Al(III) and curcumin. Though the Aβ42 neurotoxicity induced by
Al(III) (Fig. 6B-b) is higher than that of Aβ42 alone (Fig. 6B-a) and is
attenuated by curcumin (Fig. 6B-d), the neurotoxicity of Aβ42 with or
without Al(III) and curcumin presence are decreased time-dependently
(Fig. 6B), which identiﬁes the assumption inwhich the soluble oligomers
are the dominant pathological entities in AD [4]. Comparison of themor-
phology of Aβ42 with its neurotoxicity, we suppose that Al(III) promotes
the formation of Aβ42 oligomers which have substantial toxic to PC12-12
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gregates, inhibiting the formation of Aβ42 oligomers, therefore attenu-
ating the Aβ42 toxicity. On the other hand, during further incubation
of Aβ42, the formed Aβ42 oligomers assemble into the ﬁbrils which are
lower toxic than the oligomeric species, which result in an attenuation
of the Aβ42 neurotoxicity. Intriguingly, the formed Al(III)–curcumin
complexes inhibit the oligomerization and the ﬁbrillation of Aβ42,
mean while, induce the formation of amorphous aggregates, thus de-
creasing substantially the cell death.
3.5. Disaggregation of the preformed Aβ42 ﬁbrils by Al(III)–curcumin
complex
In order to evaluate the effect of curcumin on Al(III)-induced Aβ42 ﬁ-
brils, 40 μM Aβ42 was incubated in the presence of 10 μM Al(III) for
3 days to pre-form the ﬁbrils. During further 3 days of incubation of the
Aβ42 sample, the secondary structure of the preformed ﬁbrils upon the
curcumin treatment was investigated by CD spectroscopy, as shown in
Fig. 7A.When absence of curcumin, the conformation of Aβ42 changes lit-
tle during further 3 days of incubation; the conformation is comprised of25000
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at 217 nm. However, the band at 217 nm becomes less negative during
further 3 days of incubation when the concentration of curcumin is
equal to that of Al(III) of 10 μM, which indicates that Aβ42 experiences
gradually a structural transition from β-sheet structure to random coil
one. The disaggregation of the preformed ﬁbrils is also demonstrated
by ThT ﬂuorescence analysis. Fig. 7B shows that after onemore day of in-
cubation of the pre-incubated sample, the ThT ﬂuorescence intensity
reaches to a high plateau in the absence of curcumin; while in the pres-
ence of Al(III) and curcumin atmolar ratio of 1:1, the ﬂuorescence inten-
sity of the pre-incubated Aβ42 sample is decreased, which suggests that
the ﬁbrillar growth of Aβ42 is inhibited and the pre-formed β-sheet-
rich ﬁbrils is disassembled. The remodeled aggregates are also observed
by AFM images (in Fig. 7C). In the presence of curcumin, the preformed
Aβ42ﬁbrils (in Fig. 7C-I) are noticeably disassembled and remodeled into
the amorphous aggregates (in Fig. 7C-III), instead of further assembled
into theﬁbril plaques (in Fig. 7C-II) in the absence of curcumin. Above re-
sults suggest that curcumin succeeds in converting the Al(III)-inducedβ-
sheet-rich ﬁbrils into the unfolded amorphous aggregates which is low
toxic to PC12 cells (Fig. 7D).
4. Discussion
4.1. Effect of curcumin and Al(III) on Aβ42 ﬁbrillation
In combinations of the results from circular dichroism spectrosco-
py, thioﬂavin T ﬂuorescence, atomic force microscopy, Bradford and
MTT assays, the vitro experiments reported in this study provide an
unique insight into the role of Al(III), curcumin, particularly Al(III)–
curcumin complex affecting the Aβ42 morphologies and neurotoxici-
ty. Our previous work [30] demonstrated that curcumin can interact
strongly with Al(III), and form three types of complexes of [Al(III)]
[curcumin]2, [Al(III)]2[curcumin]2 and [Al(III)]2[curcumin] under dif-
ferent molar ratios of [Al]/[curcumin]. Although it is difﬁcult to deter-
mine the binding constants of such complicated systems as three
Al(III)–curcumin complexes and Al(III)–curcumin–protein by iso-
thermal titration calorimetry and UV methods, on the basis of the
present results, we suggest that the relative binding constants are in
order as: Al(III)–curcumin>Al(III)–curcumin–Aβ42>Al(III)–Aβ42>
curcumin–Aβ42.
As shown in Fig. 3D, the aggregation and ﬁbrillation kinetics of
Aβ42 appear typically sigmoidal [41]. The results show clearly that
Al(III) accelerate the random coil Aβ42 monomers aggregating into
the β-sheet ﬁbrils. Al(III) is known to bind the \COO\ group in Glu
and Asp residues and the \OH group in Ser and Tyr residues [42].
The amino acid residues bound with Al(III) are present in both hydro-
philic motifs (sequence of 1–16) and hydrophobic motifs (sequence
of 20–35) in Aβ42, more than that bound with Zn(II) and Cu(II)
which coordinate dominantly the N-terminal sequence (sequence of
1–16) of Aβ [10,43]. On one hand, binding of Al(III) to the carboxylic
groups in Aβ peptide would neutralize the electrostatic repulsions
which prevent the self-interactions between two Aβ monomers
[10], on the other hand, Al(III) might act as a “disulﬁde linkage” to
link two Aβ molecules [30,44], leading to the distance between two
Aβ molecular chains reduced, thus promoting the formation of
inter- H-bonds of Aβ; the hydrophilic residues of Aβ buried into the
interior of the molecule, and the hydrophobic residues exposed out
the exterior of the molecule [13]. As a consequence of Aβ42 binding
with Al(III), the hydrophobic motifs may assemble together to form
the folded Aβ42 aggregates and the ﬁbrils with a lowered free energy
[45]. However, when curcumin presents, the strong interaction be-
tween Al(III) and curcumin blocks the interaction between Al(III)
and Aβ42 and inhibits the ordered ﬁbrillation of Aβ42. Curcumin is a
linear ﬂat molecule (Fig. 1) like those amyloid dyes, such as Congo
red and thioﬂavin-T [40,46]. The linear ﬂat structure of curcumin ben-
eﬁts its diketo group binding the protein [47]. Moreover, these lineardye molecules bind parallel to the long axis of the ﬁbril surface in the
grooves formed by the side-chain ladders rich in aromatic amino acids
[40]. Besides, in curcuminmolecule, there are many active\OH groups
that are capable of interacting with N or O atoms in the amino residues
of Aβ42, therefore, curcumin like Congo red and thioﬂavin-T may insert
itself into the β-sheets ﬁbrils of Aβ42 [40,48], and its steric hindrance
caused by the rigid aromatic frame in curcumin might block the forma-
tion of the inter- hydrogen-bonding of Aβ42 molecules, leading to the
formation of loosely and less ordered Aβ42 structure. Interestingly, the
formed Al(III)–curcumin complexes can even remodel the preformed
Aβ42 ﬁbrils into the low neurotoxic amorphous aggregates, which is
maybe ascribed to the water solubility of the Al(III)–curcumin complex
having the diplex functions via both hydrophobic curcumin and hydro-
philic Al(III) to interact with the Aβ42 ﬁbrils, leading to the disassembly
of the ordered Aβ42 ﬁbrils into the amorphous aggregates. The Al(III)–
curcumin complex, therefore, could be considered as a inhibitor of the
oligomeric intermediates and a stabilizer of the amorphous aggregates
by inhibiting the subsequent ﬁbrillar growth of Aβ42, meanwhile, it
could be used as a disintegrator to remold theAβ42ﬁbrils into the amor-
phous aggregates.
4.2. Correlation between Aβ42 aggregate conformation, morphology and
neurotoxicity
In this work, we attempted to correlate the Aβ42 neurotoxicity with
its aggregate morphology for well understanding the biological mecha-
nismand developing the therapeutics for AD. It is found that during ﬁrst
3 days of incubation, the Aβ42 aggregates which consist mainly of the
partially folded oligomers and protoﬁbrils, have marked toxicity on
PC12 cells. However, after long time of incubation, the elongated Aβ42
aggregates which consist mainly of orderly aligned ﬁbrils and ﬁbril
plaque show low neurotoxicity. This observation identiﬁes the assump-
tion in which the soluble oligomers are main pathological entities in AD
[4]. Somemechanisms have been proposed to explain the toxicity of Aβ
oligomers, for instance, the destabilization of cell membrane, the dis-
ruption of calcium homeostasis, and the increase of oxidative stress,
while the death of cells is most likely triggered via multiple toxicity
pathways [49]. In the presence of Al(III), the formation of partially
folded Aβ42 oligomers and protoﬁbrils are accelerated, leading to the
strong neurotoxicity of the Aβ42, whereas, curcumin induces the forma-
tion of amorphous Aβ42 aggregates, and inhibits the formation of Aβ42
oligomers, therefore attenuating the Aβ42 toxicity. On the other hand,
in the presence of curcumin, the Al(III)-induced ﬁbrillation of Aβ42 is
inhibited, with the formation of the low toxic amorphous aggregates
which are mainly in random coil conformation. In addition, the pref-
ormed Aβ42 ﬁbrils are remodeled into the low toxic amorphous aggre-
gates by the formed Al(III)–curcumin complexes instead of into the
toxic ﬁbril precursors which enhance the neurotoxicity in AD.
4.3. Potential of Al(III)–curcumin complex as a novel agent for AD
treatment
A number of therapeutic strategies targeting AD have been pro-
posed, for instance, decreasing the production of Aβ, cleaning the exis-
ting aggregates from brain or blood, inhibiting the physiologic
conformational change of Aβ to its pathologicalβ-sheet formand block-
ing the formation of oligomers, protoﬁbrils, or ﬁbrils [50,51]. Up to date,
the available therapies can merely provide AD symptomatic relief, and
the issue is still fatal. Attention has been paid particularly to curcumin
for long time because the regular diet of curcumin is one of the reasons
to reduce the risk of AD in Indian [52]. Although curcumin has been
demonstrated safe and capable of passing through the blood–brain bar-
rier [52], its pharmacological application is still limited because of low
solubility and inadequate bioavailability. In this work, the formed
Al(III)–curcumin complexes can reduce the Aβ42 ﬁbrillation and neuro-
toxicity more effectively than curcumin alone. The strong ability of
1214 T. Jiang et al. / Biochimica et Biophysica Acta 1822 (2012) 1207–1215Al(III)–curcumin complex to inhibit the oligomerization and ﬁbrillation
of Aβ42 may be due to the high solubility of this complex and its strong
interaction with Aβ42. As reported in our previous work [30], curcumin
can chelate Al(III) ions stably via its active enol-H groups to form three
types of complexes with Al(III) in molar ratios of 1:2, 1:1 and 2:1 [30],
and the Al(III) in Al(III)–curcumin complexes not only chelates curcumin,
but also interacts withwatermolecules, which lead to the formed Al(III)–
curcumin complexes more hydrophilic. The soluble Al(III)–curcumin
complexesmay bind to Aβ42 by both\OH groups in curcumin and active
Al(III), allowing its interaction more efﬁcient than curcumin alone.
Although aluminum element was reported to act as a neurological
toxicant and provoke the embryonic and fetal toxicity on animal and
human after gestational exposure [53], it still remains unclear whether
long-term exposure or accumulation of even small amounts of aluminum
in human body can result in the clinically toxic effects [54]. Normally, alu-
minum is absorbed via the gastrointestinal tract and excreted primarily
by kidneys or bile. Though its biological or physiological roles are still
unclear, aluminum is able tomake use of transferrin, an iron-carried plas-
ma protein, to across the blood–brain barrier into the brain tissue [55].
Many aluminum-contained drugs such as antacids and somebuffered an-
algesics are ingested over a long period of time and considered to be suf-
ﬁciently safe for sale over-the-counter (OTC) [56]. In addition, aluminum
salts are also used as the pharmaceutical excipients or adjuvants in the
preparation of a number of vaccines, toxoids and allergen injectants. On
the basis of the above discussion, Al(III)–curcumin complex, in the appro-
priate dose and the complex form, ismaybeworth potentially developing
as a therapy agent against the neurodegenerative disorders in the future.
Conﬂict of interest
The authors declare that there are no conﬂicts of interest.
Author contribution
Conceived and designed the research: PZ, TJ, LFP. Performed the
experiments: TJ. Analyzed the data: PZ, TJ, XLZ. Wrote the paper: PZ,
TJ, YHZ, XLZ.
Acknowledgements
The work was supported by the Natural Science Foundation of
China (Nos. 10475017, 20673022, 21074025), Action Plan of Science
and Technology Innovation, Science and Technology Commission of
Shanghai Municipality (No. 11DZ1971802), and Research Innovation
Project, Education Commission of Shanghai Municipality (No.
12ZZ009).
References
[1] K.J. Barnham, D.G. Smith, R. Cappai, The redox chemistry of the Alzheimer's dis-
ease amyloid beta peptide, Bba-Biomembranes 1768 (2007) 1976–1990.
[2] C.J. Pike, A.J.Walencewicz, C.G. Glabe, C.W. Cotman, Invitro agingof beta-amyloid pro-
tein causes peptide aggregation and neurotoxicity, Brain Res. 563 (1991) 311–314.
[3] J.L. Cummings, H.V. Vinters, G.M. Cole, Z.S. Khachaturian, Alzheimer's disease—
etiologies, pathophysiology, cognitive reserve, and treatment opportunities, Neu-
rology 51 (1998) S2–S17.
[4] Y.R. Chen, C.L. Ni, H.P. Shi, H.M. Yu, Y.C. Chang, Folding stability of amyloid-beta
40 monomer is an important determinant of the nucleation kinetics in
ﬁbrillization, FASEB J. 25 (2011) 1390–1401.
[5] C. Haass, D.J. Selkoe, Soluble protein oligomers in neurodegeneration: lessons
from the Alzheimer's amyloid beta-peptide, Nat. Rev. Mol. Cell Biol. 8 (2007)
101–112.
[6] V. Raussens, E. Cerf, A. Gustot, E. Goormaghtigh, J.M. Ruysschaert, High ability of
apolipoprotein E4 to stabilize amyloid-beta peptide oligomers, the pathological
entities responsible for Alzheimer's disease, FASEB J. 25 (2011) 1585–1595.
[7] J. Bieschke, J. Russ, R.P. Friedrich, D.E. Ehrnhoefer, H. Wobst, K. Neugebauer, E.E.
Wanker, EGCG remodels mature alpha-synuclein and amyloid-beta ﬁbrils and re-
duces cellular toxicity, Proc. Natl. Acad. Sci. U. S. A. 107 (2010) 7710–7715.
[8] P. Zatta, R. Lucchini, S.J. van Rensburg, A. Taylor, The role of metals in neurodegenera-
tive processes: aluminum, manganese, and zinc, Brain Res. Bull. 62 (2003) 15–28.[9] C. Exley, E. House, J. Collingwood, A. Khan, O. Korchazkina, G. Berthon, Alumini-
um, iron, zinc and copper inﬂuence the in vitro formation of amyloid ﬁbrils of A
beta(42) in a manner which may have consequences for metal chelation therapy
in Alzheimer's disease, J. Alzheimers Dis. 6 (2004) 291–301.
[10] P. Zatta, F. Ricchelli, D. Drago, B. Filippi, G. Tognon, Aluminum-triggered structural
modiﬁcations and aggregation of beta-amyloids, Cell. Mol. Life Sci. 62 (2005)
1724–1733.
[11] C. Exley, Aluminium and iron, but neither copper nor zinc, are key to the precip-
itation of beta-sheets of A beta(42) in senile plaque cores in Alzheimer's disease,
J. Alzheimers Dis. 10 (2006) 173–177.
[12] P. Nayak, Aluminum: impacts and disease, Environ. Res. 89 (2002) 101–115.
[13] D. Drago, M. Bettella, S. Bolognin, L. Cendron, J. Scancar, R. Milacic, F. Ricchelli, A.
Casini, L. Messori, G. Tognon, P. Zatta, Potential pathogenic role of beta-
amyloid(1–42)-aluminum complex in Alzheimer's disease, Int. J. Biochem. Cell
Biol. 40 (2008) 731–746.
[14] T. Sakamoto, H. Saito, K. Ishii, H. Takahashi, S. Tanabe, Y. Ogasawara, Aluminum
inhibits proteolytic degradation of amyloid beta peptide by cathepsin D: a poten-
tial link between aluminum accumulation and neuritic plaque deposition, FEBS
Lett. 580 (2006) 6543–6549.
[15] J. Savory, C. Exley, W.F. Forbes, Y. Huang, J.G. Joshi, T. Kruck, D.R.C. McLachlan, I.
Wakayama, Can the controversy of the role of aluminum in Alzheimer's disease
be resolved?What are the suggested approaches to this controversy andmethod-
ological issues to be considered? J. Toxicol. Environ. Health 48 (1996) 615–635.
[16] M. Clauberg, J.G. Joshi, Regulation of serine protease activity by aluminum—
implications for Alzheimer-disease, Proc. Natl. Acad. Sci. U. S. A. 90 (1993) 1009–1012.
[17] D. Pratico, K. Uryu, S. Sung, S. Tang, J.Q. Trojanowski, V.M.Y. Lee, Aluminum mod-
ulates brain amyloidosis through oxidative stress in APP transgenic mice, FASEB J.
16 (2002) 1138–1140.
[18] P. Zatta, M.L. Hegde, P. Bharathi, A. Suram, C. Venugopal, R. Jagannathan, P.
Poddar, P. Srinivas, K. Sambamurti, K.J. Rao, J. Scancar, L. Messori, L. Zecca, Chal-
lenges associated with metal chelation therapy in Alzheimer's disease,
J. Alzheimers Dis. 17 (2009) 457–468.
[19] C. Rodriguez-Rodriguez, N.S. de Groot, A. Rimola, A. Alvarez-Larena, V. Lloveras, J.
Vidal-Gancedo, S. Ventura, J. Vendrell, M. Sodupe, P. Gonzalez-Duarte, Design, se-
lection, and characterization of thioﬂavin-based intercalation compounds with
metal chelating properties for application in Alzheimer's disease, J. Am. Chem.
Soc. 131 (2009) 1436–1451.
[20] H.T. Li, D.H. Lin, X.Y. Luo, F. Zhang, L.N. Ji, H.N. Du, G.Q. Song, J. Hu, J.W. Zhou, H.Y.
Hu, Inhibition of alpha-synuclein ﬁbrillization by dopamine analogs via reaction
with the amino groups of alpha-synuclein, FEBS J. 272 (2005) 3661–3672.
[21] G.J. Kelloff, J.A. Crowell, E.T. Hawk, V.E. Steele, R.A. Lubet, C.W. Boone, J.M. Covey,
L.A. Doody, G.S. Omenn, P. Greenwald, W.K. Hong, D.R. Parkinson, D. Bagheri, G.T.
Baxter, M. Blunden, M.K. Doeltz, K.M. Eisenhauer, K. Johnson, G.G. Knapp, D.G.
Longfellow, W.F. Malone, S.G. Nayﬁeld, H.E. Seifried, L.M. Swall, C.C. Sigman, Clin-
ical development plans for cancer chemopreventive agents, J. Cell. Biochem.
(1996) 72–321.
[22] J.E. Galvin, N. Pandey, J. Strider, W.C. Nolan, S.X. Yan, Curcumin inhibits aggrega-
tion of alpha-synuclein, Acta Neuropathol. 115 (2008) 479–489.
[23] S. Mishra, K. Palanivelu, The effect of curcumin (turmeric) on Alzheimer's disease:
an overview, Ann. Indian Acad. Neurol. 11 (2008) 13–19.
[24] G.P. Lim, T. Chu, F.S. Yang, W. Beech, S.A. Frautschy, G.M. Cole, The curry spice cur-
cumin reduces oxidative damage and amyloid pathology in an Alzheimer trans-
genic mouse, J. Neurosci. 21 (2001) 8370–8377.
[25] M. Garcia-Alloza, L.A. Borrelli, A. Rozkalne, B.T. Hyman, B.J. Bacskai, Curcumin la-
bels amyloid pathology in vivo, disrupts existing plaques, and partially restores
distorted neurites in an Alzheimer mouse model, J. Neurochem. 102 (2007)
1095–1104.
[26] K.I. Priyadarsini, A. Barik, B. Mishra, L. Shen, H. Mohan, R.M. Kadam, S. Dutta, H.Y.
Zhang, Evaluation of a new copper(II)–curcumin complex as superoxide dis-
mutase mimic and its free radical reactions, Free Radic. Biol. Med. 39 (2005)
811–822.
[27] X.Z. Zhao, T. Jiang, L. Wang, H. Yang, S. Zhang, P. Zhou, Interaction of curcumin
with Zn(II) and Cu(II) ions based on experiment and theoretical calculation,
J. Mol. Struct. 984 (2010) 316–325.
[28] D.H. Xu, X.T. Mei, S.K. Xu, Y.P. Zheng, S.B. Xu, Gastroprotective and antidepressant
effects of a new zinc(II)–curcumin complex in rodent models of gastric ulcer and
depression induced by stresses, Pharmacol. Biochem. Behav. 99 (2011) 66–74.
[29] M.B.H. Youdim, S. Mandel, T. Amit, O. Bar-Am, Iron dysregulation in Alzheimer's dis-
ease:multimodal brain permeable iron chelatingdrugs, possessing neuroprotective-
neurorescue and amyloid precursor protein-processing regulatory activities as ther-
apeutic agents, Prog. Neurobiol. 82 (2007) 348–360.
[30] T. Jiang, L. Wang, S. Zhang, P.C. Sun, C.F. Ding, Y.Q. Chu, Z. Ping, Interaction of cur-
cumin with Al(III) and its complex structures based on experiments and theoret-
ical calculations, J. Mol. Struct. 1004 (2011) 163–173.
[31] O. Vajragupta, P. Boonchoong, H. Watanabe, M. Tohda, N. Kummasud, Y.
Sumanont, Manganese complexes of curcumin and its derivatives: evaluation
for the radical scavenging ability and neuroprotective activity, Free Radic. Biol.
Med. 35 (2003) 1632–1644.
[32] B.B. Aggarwal, P. Anand, C. Sundaram, S. Jhurani, A.B. Kunnumakkara, Curcumin
and cancer: an “old-age” disease with an “age-old” solution, Cancer Lett. 267
(2008) 133–164.
[33] B.B. Aggarwal, P. Anand, A.B. Kunnumakkara, R.A. Newman, Bioavailability of cur-
cumin: problems and promises, Mol. Pharmaceutics 4 (2007) 807–818.
[34] H.X. Lou, A.C. Liu, L.X. Zhao, P.H. Fan, Validated LC/MS/MS assay for curcumin and
tetrahydrocurcumin in rat plasma and application to pharmacokinetic study of
phospholipid complex of curcumin, J. Pharmaceut. Biomed. 40 (2006) 720–727.
1215T. Jiang et al. / Biochimica et Biophysica Acta 1822 (2012) 1207–1215[35] S.K. Sahoo, C. Mohanty, The in vitro stability and in vivo pharmacokinetics of cur-
cumin prepared as an aqueous nanoparticulate formulation, Biomaterials 31
(2010) 6597–6611.
[36] B.B. Aggarwal, P. Anand, S.G. Thomas, A.B. Kunnumakkara, C. Sundaram, K.B.
Harikumar, B. Sung, S.T. Tharakan, K. Misra, I.K. Priyadarsini, K.N. Rajasekharan,
Biological activities of curcumin and its analogues (Congeners) made by man
and Mother Nature, Biochem. Pharmacol. 76 (2008) 1590–1611.
[37] V.A. Streltsov, S.J. Titmuss, V.C. Epa, K.J. Barnham, C.L. Masters, J.N. Varghese, The
structure of the amyloid-beta peptide high-afﬁnity copper II binding site in
Alzheimer disease, Biophys. J. 95 (2008) 3447–3456.
[38] M.R. Sierks, R. Liu, H. Barkhordarian, S. Emadi, C.B. Park, Trehalose differentially
inhibits aggregation and neurotoxicity of beta-amyloid 40 and 42, Neurobiol.
Dis. 20 (2005) 74–81.
[39] M. Biancalana, S. Koide, Molecular mechanism of thioﬂavin-T binding to amyloid
ﬁbrils, Bba-Proteins Proteomics 1804 (2010) 1405–1412.
[40] M.R.H. Krebs, E.H.C. Bromley, A.M. Donald, The binding of thioﬂavin-T to amyloid
ﬁbrils: localisation and implications, J. Struct. Biol. 149 (2005) 30–37.
[41] N.P. Ulrih, C.H. Barry, A.L. Fink, Impact of Tyr to Ala mutations on alpha-synuclein
ﬁbrillation and structural properties, Bba-Mol. Basis Dis. 1782 (2008) 581–585.
[42] G.D. Fasman, Aluminum and Alzheimer's disease: model studies, Coord. Chem.
Rev. 149 (1996) 125–165.
[43] T. Miura, K. Suzuki, N. Kohata, H. Takeuchi, Metal binding modes of Alzheimer's
amyloid beta-peptide in insoluble aggregates and soluble complexes, Biochemis-
try-Us 39 (2000) 7024–7031.
[44] J.W. Akitt, W. Gessner, Al-27 nuclear magnetic-resonance investigations of highly
alkaline aluminate solutions, J. Chem. Soc. Dalton (1984) 147–148.
[45] N.A.M. Besseling, J. Lyklema, Molecular thermodynamics of hydrophobic hydra-
tion, J. Phys. Chem. B 101 (1997) 7604–7611.[46] W.E. Klunk, J.W. Pettegrew, D.J. Abraham, Quantitative-evaluation of Congo Red
binding to amyloid-like proteins with a beta-pleated sheet conformation, J. Histo-
chem. Cytochem. 37 (1989) 1273–1281.
[47] F.S. Yang, G.P. Lim, A.N. Begum, O.J. Ubeda, M.R. Simmons, S.S. Ambegaokar, P.P.
Chen, R. Kayed, C.G. Glabe, S.A. Frautschy, G.M. Cole, Curcumin inhibits formation
of amyloid beta oligomers and ﬁbrils, binds plaques, and reduces amyloid in vivo,
J. Biol. Chem. 280 (2005) 5892–5901.
[48] G. Romhanyi, Selective differentiation between amyloid and connective tissue
structures based on collagen speciﬁc topo-optical staining reaction with Congo
Red, Virchows Arch. A 354 (1971) 209–222.
[49] M. Sakono, T. Zako, Amyloid oligomers: formation and toxicity of A beta oligo-
mers, FEBS J. 277 (2010) 1348–1358.
[50] J.J. Valle-Delgado, M. Alfonso-Prieto, N.S. de Groot, S. Ventura, J. Samitier, C.
Rovira, X. Fernandez-Busquets, Modulation of A beta(42) ﬁbrillogenesis by gly-
cosaminoglycan structure, FASEB J. 24 (2010) 4250–4261.
[51] H. LeVine, The challenge of inhibiting A beta polymerization, Curr. Med. Chem. 9
(2002) 1121–1133.
[52] F.M. Tortia, H. Hatcher, R. Planalp, J. Cho, S.V. Torti, Curcumin: from ancient med-
icine to current clinical trials, Cell. Mol. Life Sci. 65 (2008) 1631–1652.
[53] K.S.J. Rao, V.B. Gupta, S. Anitha, M.L. Hegde, L. Zecca, R.M. Garruto, R. Ravid, S.K.
Shankar, R. Stein, P. Shanmugavelu, Aluminium in Alzheimer's disease: are we
still at a crossroad? Cell. Mol. Life Sci. 62 (2005) 143–158.
[54] J.B. Cannata-Andia, Reconsidering the importance of long-term low-level alumi-
num exposure in renal failure patients, Semin. Dial. 14 (2001) 5–7.
[55] R.A. Yokel, The toxicology of aluminum in the brain: a review, Neurotoxicology 21
(2000) 813–828.
[56] C.M. Reinke, J. Breitkreutz, H. Leuenberger, Aluminium in over-the-counter drugs
—risks outweigh beneﬁts? Drug Saf. 26 (2003) 1011–1025.
